Prepare for a game-changing collaboration! InnoSer and CR2O unveil their strategic partnership, bridging the gap between pre-clinical and clinical research. Join us as we revolutionize drug discovery and development with an integrated platform poised to accelerate groundbreaking treatments to market.
Read the full press release unveiling this transformative alliance!
Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and U.S. firms.
The full innovation journey offering for Biointelect, a strategic life science consulting company, and CR2O, a leading contract research organisation, has reached new heights, with Australian, European and U.S. clients now able to tap into world-class strategic advice and full-service clinical trial capabilities following the announcement of Biointelect’s and CR2O’s new strategic partnership.
Biointelect and CR2O will work to provide our clients solutions across geographical boundaries and rapidly navigate an increasingly complex regulatory, access, policy and clinical landscape. Based in the Netherlands, CR2O is expanding Biointelect’s existing capability to include clinical trial capabilities across the European Union and Australia. The partnership will give CR2O access to Biointelect’s strategic product development consultancy and commercialisation capabilities.
The transformational move puts Biointelect and CR2O at the forefront for providing world-class innovative end-to-end commercialisation solutions to streamline project work across every phase of the development cycle.
Biointelect CEO Leah Goodman said ultimately this collaborative partnership will mean strengthened confidence for clients in reaching their goals and an enhanced customer experience with a focus on performance.
“We are delighted that our partnership with CR2O enhances the full value Biointelect brings to our clients, completing our partnership capability from early research right through to commercialisation.”
“The alliance with CR2O will generate even greater returns to clients across the full innovation journey via a consolidated service offer with a trusted partner.”
“Biointelect’s reputation for quality is a common value with CR2O, and we are confident that together this global expansion will continue to enable our collaboration with Life science partners in enhancing the ecosystem and bringing innovation to patients,” Goodman added.
Trusted connections
The strategic partnership harnesses the deep insights, ground support and local presence of both CR2O and Biointelect for Australian, European and U.S. clients across the pharmaceutical and biotechnology industries.
Core to the advancement strategy is an understanding of the macroeconomic and geopolitical tensions that often impact the sector, to deliver fit-for-purpose clinical development solutions that de-risk the pathway to patient care settings.
CR2O CEO Hadil Es-Sbai believes the partnership with Biointelect will strengthen strategic capabilities by leveraging established relationships with stakeholders to provide advanced end-to-end commercialisation solutions for clients.
“We are very pleased to strengthen our collaboration with Biointelect by leveraging their world-class strategic planning and commercialisation capabilities for the benefit of our pharmaceutical and biotechnology clients. Together we offer integrated, fit-for-purpose clinical development solutions that de-risk the complex journey from bench to bedside,” said Es Sbai.
Performance driven
The new partnership has ushered in a wave of enquiries from universities, government, biotechnology and pharmaceutical companies seeking a wholistic, one-stop-shop for tailored solutions across the full innovation journey. With a synergy in values underpinning the partnership’s success, both will leverage their proven track records to continue a trajectory of bringing life science innovations to market.
“At the end of the day, our aim is to deliver outstanding results for our clients through an efficient and accelerated approach with a focus on reliability and credibility. Our partnership with CR2O enhances our ability to provide value to our now shared clients.” Goodman said.
SpokespeopleAustralia: Biointelect CEO Leah Goodman
With a career spanning executive leadership roles at Bristol-Myers Squibb, Merck Healthcare, and Sanofi, Leah has excelled in diverse therapeutic areas, from immunooncology to primary care. She has significant experience successfully leading Multinational company business transformation and growth in Australia and across Asia including South East Asia, Korea, and Japan. In November 2023, Leah commenced as Chief Executive Officer at Biointelect. Drawing on her extensive leadership background, she has embarked on successfully engaging the company to a this new strategic vision and long term success.
CR2O is a leading European clinical CRO, specialised in managing and operating early-stage infectious disease clinical trials. Artemis Bioservices is a specialty lab, evaluating viral vaccines and antiviral therapeutics, in particular against emerging, zoonotic and vector-borne diseases.
For several years, CR2O and Artemis Bioservices have teamed up to advance industry- and public partners’ compounds from bench to various stages of clinical development. Together we offer more value to our partners by combining scientific expertise and operational excellence, under strict regulatory and quality requirements.
“We are very pleased with the successful collaboration with Artemis Biosciences lab in the recently concluded Phase-I studies investigating novel vaccines against Rift Valley Fever and SARS-CoV-2.” – Hadil Es-Sbai, CEO CR2O
“Our scientists and operational experts in virology, immunology and vaccinology, work hand-in-glove with our partners to deliver their projects within specifications.” – Byron Martina, CEO Artemis Biosciences
A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a well-organized set of action plans needs to be in place that guides and accelerates the client’s vision on how to support their targeted therapeutic area.
CR2O (cr2o.nl) and 3D-PharmXchange (3d-pxc.com) are celebrating 2 years of successful ongoing collaboration on a number of pre- and clinical development programs for Biotech/Pharma SMEs. Together we designed, planned, oversaw and optimized multiple clinical-stage development programs. Amongst others our partnership has led to a well-defined CMC, regulatory and clinical development strategy for a new drug treating Female Sexual Disfunction including obtaining scientific and technical advice at EMA and FDA paving the way for the start of confirmatory trials in Europe and US.
Both companies also joined forces in delivering CMC, clinical development and clinical operational expertise allowing a vaccine produced on a new innovative yeast based production platform to be tested in a First-in-Human study. The use of this novel platform will lead to affordable, scalable, protective and safe vaccines.
Our highly qualified and experienced Life Sciences professionals are supported by CR2O’s rigorous clinical quality management system and continuous training programs, enabling delivery of top-quality clinical services. Senior experts were selected based on their ability to answer to the client’s development program’s specific requirements. The combined teams of Non-Clinical, Clinical, CMC and Regulatory experts all had hands-on experience from leading Big Pharma company teams.
Going from bench to the patient’s bedside is the dream of any scientist. Working smarter can make this goal a reality. Having a clear plan and guidance from the first tests all the way to the final drug product is crucial. Being able to combine CR2O’s operational clinical expertise with Clinical Science, CMC, Regulatory Affairs and Non-Clinical expertise was shown to be vital in those projects.
CR2O and 3D-PharmXchange remain committed with enthusiasm to the responsibilities that we assumed together towards customers and partners. We have successfully inspired difficult projects with novel ideas and insights, thereby significantly increasing the chance of success. We are constantly developing and stimulating ourselves to be able to take on the challenges of our complex field with pride.
Dutch industry magazine Biotech NEWS and Life Sciences has profiled CR2O in their 2020 Winter edition.
Biotech NEWS and Life Sciences is a national magazine reporting on trends and news within health and life sciences in The Netherlands. During the interview with CR2O, management team members Cari, Ellemieke, and Nick explain how CR2O has seen considerable growth over the past years, and why CR2O is an early phase clinical trial expert that is ‘big enough to deliver, small enough to care’.
To read the full article and learn more on CR2O’s background, recent clinical trials, and core expertise, you can find the November edition of Biotech News and Life Sciences magazine by clicking here.
As a result of the COVID-19 pandemic, CR2O has adapted its contingency plan aimed to guarantee the safety and well-being of patients, employees, clients and continuity of our services. By following recommendations from Regulatory Authorities (local, EMA and FDA), CR2O continues to focus on patient safety and maintaining compliance with GCP under the current restrictive circumstances.
CR2O will remain fully operational during the COVID-19 pandemic.
If you have any question, please contact us on: info@CR2O.nl / +31 (0)85-071 74 01.
